UNSPSC 51272101: Parethoxycaine

This classification denotes an anesthetic agent with the molecular formula C15H23NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 68E52E5J67, chemically known as benzoic acid, p-ethoxy-, 2-(diethylamino)ethyl ester but generally known as parethoxycaine, which bears US NIH Compound Identifier 7183. European Medicines Agency schedules Parethoxycaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09624MIG. The term PARETHOXYCAINE is an International Non-Proprietary Name.

UNSPSC 51272101 Parethoxycaine, a Commodity code, represents a narrow pharmaceutical ingredient category that state and local governments rarely procure directly. The recent solicitations tagged under this code reveal a substantial mismatch: the opportunities actually being purchased include finished naloxone products, over-the-counter pharmaceuticals, generic multi-source drugs, and direct-to-manufacturer prescription programs—none of which are parethoxycaine or its precursor compounds. Seminole County, Florida's IFB for naloxone and drug deactivation systems, the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription fulfillment, and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic pharmaceuticals and OTC products all center on end-use medications and supply-chain intermediation rather than on active pharmaceutical ingredients or local anesthetics. The code shows little relevant recent activity for firms selling parethoxycaine itself.

No state or local procurement opportunities in the past six months target parethoxycaine as a line item or as part of a defined pharmaceutical ingredient procurement. The issuing bodies active in pharmaceutical procurement—Seminole County, the Texas HHS Commission, and MMCAP—are sourcing finished products through wholesaler networks and direct manufacturer relationships, not ingredient suppliers. Firms pursuing state and local pharmaceutical work should monitor the broader generic-drug and OTC-product family codes (such as finished-formulation codes) and cooperative purchasing vehicles like MMCAP rather than expect demand under this ingredient-specific Commodity code.